Edgewise Therapeutics, Inc.
General ticker "EWTX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.9B (TTM average)
Edgewise Therapeutics, Inc. follows the US Stock Market performance with the rate: 6.1%.
Estimated limits based on current volatility of 4.0%: low 22.96$, high 24.85$
Factors to consider:
- Total employees count: 110 (+25.0%) as of 2024
- Top business risk factors: Limited operating history and commercial readiness, Operational and conduct risks, Dependence on successful product commercialization, Need for additional capital, Labor/talent shortage/retention
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [15.92$, 36.66$]
- 2025-12-31 to 2026-12-31 estimated range: [11.17$, 27.08$]
Financial Metrics affecting the EWTX estimates:
- Negative: with PPE of -20.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -4.03 <= 0.33
- Positive: Shareholder equity ratio, % of 94.33 > 63.39
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: -0.75 < Inventory ratio change, % of 0
- Positive: -14.38 < Investing cash flow per share per price, % of -6.83
Short-term EWTX quotes
Long-term EWTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $71.66MM | $114.36MM | $158.83MM |
| Operating Income | $-71.66MM | $-114.36MM | $-158.83MM |
| Non-Operating Income | $4.02MM | $14.19MM | $25.02MM |
| R&D Expense | $54.03MM | $90.91MM | $126.97MM |
| Income(Loss) | $-67.64MM | $-100.16MM | $-133.81MM |
| Profit(Loss)* | $-67.64MM | $-100.16MM | $-133.81MM |
| Stockholders Equity | $346.72MM | $318.83MM | $459.22MM |
| Assets | $367.10MM | $340.04MM | $486.82MM |
| Operating Cash Flow | $-52.63MM | $-91.95MM | $-109.03MM |
| Capital expenditure | $5.55MM | $5.75MM | $1.31MM |
| Investing Cash Flow | $-70.58MM | $102.89MM | $-184.66MM |
| Financing Cash Flow | $129.64MM | $53.17MM | $249.25MM |
| Earnings Per Share** | $-1.26 | $-1.57 | $-1.45 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.